…
Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Acusphere Inc (ACUS.US) is an OTC Pink–listed company for which public disclosures about operations, products, and financial condition are sparse, preventing a clear description of its core business. Major long-term growth drivers cannot be identified from available filings, and investors may find the company attractive only if future validated disclosures and credible strategic or financial plans emerge.
The most important risks are very low trading liquidity, regulatory and listing risks associated with Pink-tier securities, potential lack of access to capital and high share-price volatility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 |
| Income before tax | -67.73M | 51.46M | 63.20M | 46.43M | 30.47M |
| Net income | -67.73M | -53.73M | -61.09M | -44.63M | -29.96M |
| Selling general administrative | 10.70M | 16.17M | 14.66M | 10.47M | 27.30M |
| Gross profit | -31.77M | 2.67M | 1.78M | 3.43M | 1.71M |
| Ebit | -42.47M | -51.46M | -63.20M | -46.43M | -30.47M |
| Ebitda | - | -43.67M | -52.91M | -42.43M | -29.10M |
| Depreciation and amortization | - | 7.80M | 10.29M | 4.01M | 1.37M |
| Operating income | -42.47M | 52.73M | 62.28M | 46.18M | 30.43M |
| Other operating expenses | - | 55.39M | 64.06M | 49.61M | 32.14M |
| Interest expense | 0.00M | 2.05M | 2.27M | 0.55M | 0.13M |
| Income tax expense | 0.00M | 1.00M | -1.19M | -1.55M | -0.47M |
| Total revenue | 2.68M | 2.67M | 1.78M | 3.43M | 1.71M |
| Total operating expenses | 45.16M | 55.39M | 64.06M | 49.61M | 32.14M |
| Cost of revenue | 34.45M | 39.23M | 47.91M | 33.92M | 3.47M |
| Total other income expense net | -25.26M | -1.26M | 0.92M | 0.26M | 0.04M |
| Net income from continuing ops | -67.73M | -53.73M | -61.09M | -44.62M | - |
| Net income applicable to common shares | -69.42M | -56.01M | -63.47M | -47.04M | - |
| Breakdown | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 |
| Total assets | 23.11M | 52.02M | 94.82M | 95.84M | 62.00M |
| Other current assets | 1.25M | 1.26M | 0.84M | 1.14M | 2.10M |
| Total liab | 51.62M | 28.28M | 36.37M | 38.42M | 16.49M |
| Total stockholder equity | -28.50M | 23.74M | 58.45M | 57.42M | 45.51M |
| Deferred long term liab | - | - | 4.67M | 2.58M | - |
| Other current liab | 13.93M | 3.61M | 4.14M | 7.91M | 8.79M |
| Common stock | -28.50M | 0.46M | 0.38M | 0.23M | 0.18M |
| Retained earnings | - | -334.87M | -281.14M | -220.05M | -175.43M |
| Other liab | 14.44M | 3.07M | 12.37M | 8.14M | 0.86M |
| Other assets | 5.41M | 1.60M | 1.84M | 3.55M | 1.86M |
| Cash | 16.45M | 26.10M | 59.75M | 51.11M | 45.18M |
| Total current liabilities | 13.93M | 18.83M | 22.32M | 21.24M | 13.13M |
| Current deferred revenue | - | 4.67M | 2.67M | 3.43M | 3.43M |
| Net debt | - | -8.09M | -37.47M | -29.78M | -41.61M |
| Short term debt | 23.25M | 8.56M | 12.90M | 6.73M | 1.07M |
| Short long term debt | 23.25M | 4.93M | 12.90M | 6.73M | - |
| Short long term debt total | - | 18.01M | 22.28M | 21.33M | 3.57M |
| Other stockholder equity | - | 358.14M | 678.45M | 555.18M | 221.67M |
| Property plant equipment | - | 23.05M | 32.39M | 40.03M | 12.87M |
| Total current assets | 17.70M | 27.37M | 60.59M | 52.25M | 47.28M |
| Net tangible assets | -28.50M | 23.73M | 58.44M | 57.41M | - |
| Long term debt | 23.25M | 6.34M | 1.68M | 9.03M | 2.50M |
| Accounts payable | - | 1.99M | 2.62M | 3.18M | 4.24M |
| Accumulated other comprehensive income | - | - | -0.02M | -0.36M | -0.91M |
| Preferred stock total equity | - | 0.01M | 0.01M | 0.01M | - |
| Non currrent assets other | - | 1.41M | 1.78M | 1.75M | 1.86M |
| Non current assets total | - | 24.65M | 34.23M | 43.59M | 14.73M |
| Breakdown | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 |
| Change to liabilities | 0.00M | -0.63M | 2.26M | 4.09M | 4.98M |
| Total cashflows from investing activities | - | -0.99M | -1.22M | -32.87M | - |
| Net borrowings | - | -7.51M | -1.36M | 12.19M | - |
| Total cash from financing activities | - | 9.05M | 57.95M | 69.48M | 22.38M |
| Change to operating activities | - | -1.05M | -2.46M | 2.16M | - |
| Net income | -67.73M | -53.73M | -61.09M | -44.63M | -29.96M |
| Change in cash | - | -33.65M | 8.64M | 5.93M | -9.38M |
| Begin period cash flow | 26.10M | 59.75M | 51.11M | 45.18M | 54.56M |
| End period cash flow | - | 26.10M | 59.75M | 51.11M | 45.18M |
| Total cash from operating activities | - | -41.71M | -48.09M | -30.68M | -19.32M |
| Depreciation | - | 7.80M | 10.29M | 4.01M | 1.37M |
| Other cashflows from investing activities | - | 0.00M | -0.13M | 0.11M | - |
| Dividends paid | - | 2.27M | 2.38M | 2.22M | - |
| Sale purchase of stock | - | 18.83M | 61.69M | 17.62M | - |
| Other cashflows from financing activities | - | -7.51M | -1.36M | 12.19M | 0.00M |
| Change to netincome | - | 3.46M | 2.92M | 3.68M | - |
| Capital expenditures | 0.00M | 1.00M | 1.09M | 32.98M | 12.18M |
| Change in working capital | - | -1.68M | -0.21M | 6.25M | 9.59M |
| Other non cash items | - | 5.90M | 2.92M | 3.68M | -0.32M |
| Free cash flow | - | -42.70M | -49.18M | -63.66M | -31.50M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. William I. Ramage D.Phil | Chief Devel. Officer | 1954 |
| Dr. William I. Ramage D.Phil | Chief Development Officer | 1954 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.